STOCK TITAN
  1. Home
  2. Sec-filings
  3. MGX
  4. [Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity

Metagenomi Therapeutics (NASDAQ: MGX) CFO has shares sold to cover taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Metagenomi Therapeutics, Inc. reported that Chief Financial Officer Pamela Wapnick had 2,884 shares of common stock sold at $1.299 per share. According to the footnote, these shares were automatically sold to cover tax withholding on vested restricted stock units and were not a discretionary trade. Following the transaction, she directly holds 208,491 shares.

Positive

  • None.

Negative

  • None.
Insider Wapnick Pamela
Role Chief Financial Officer
Sold 2,884 shs ($4K)
Type Security Shares Price Value
Sale Common Stock 2,884 $1.299 $4K
Holdings After Transaction: Common Stock — 208,491 shares (Direct)
Footnotes (1)
  1. [object Object]
Shares sold 2,884 shares Common stock automatically sold on 2026-06-05
Sale price $1.299 per share Price for the 2,884 common shares sold
Shares held after 208,491 shares Direct ownership following the transaction
Net shares sold 2,884 shares Net-sell per transaction summary
restricted stock units financial
"upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units"
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Metagenomi Therapeutics (MGX) disclose in this Form 4 for its CFO?
Metagenomi Therapeutics reported that CFO Pamela Wapnick had 2,884 common shares sold at $1.299 each. The filing explains the sale was automatic to satisfy tax withholding on vested restricted stock units, not a discretionary market trade.

Was the Metagenomi (MGX) CFO’s Form 4 transaction a voluntary stock sale?
No, the Form 4 states the shares were automatically sold to meet tax withholding obligations from RSU vesting. The footnote clarifies it does not represent a volitional trade by Chief Financial Officer Pamela Wapnick in the open market.

How many Metagenomi (MGX) shares were involved in the CFO’s recent Form 4?
The Form 4 shows 2,884 shares of Metagenomi common stock were sold at $1.299 per share. These shares came from restricted stock units that vested and were sold solely to cover related tax withholding obligations.

How many Metagenomi (MGX) shares does the CFO hold after this Form 4 transaction?
After the automatic sale for tax withholding, Chief Financial Officer Pamela Wapnick directly holds 208,491 shares of Metagenomi common stock. The Form 4 provides this post-transaction ownership figure as part of the non-derivative holdings table.

Why were Metagenomi (MGX) shares sold in connection with RSU vesting?
The footnote explains shares were automatically sold to satisfy the CFO’s tax withholding obligations when restricted stock units granted on April 1, 2024 and April 1, 2025 vested. This mechanism settles taxes without requiring separate cash payments.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wapnick Pamela
(Last)(First)(Middle)
C/O METAGENOMI THERAPEUTICS, INC.
5959 HORTON STREET, 7TH FLOOR
(Street)
EMERYVILLE CALIFORNIA 94608
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Metagenomi Therapeutics, Inc. [ MGX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/05/2026S(1)2,884D$1.299208,491D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person.
/s/ Matthew L. Wein, attorney-in-fact06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR